权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SPORE for Translational Approaches to Brain Cancer

SPORE 用于脑癌转化方法

基本信息

批准号：
10478866
负责人：
MACIEJ S LESNIAK
金额：
$ 213.9万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-17 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10478866
关键词：
Address Adult Animals Apoptosis Autophagocytosis Brain Brain Neoplasms Cells Clinical Clinical Trials Collaborations Combined Modality Therapy Complex Cytolysis Cytotoxic Chemotherapy Diagnosis Disease Faculty Genes Glioblastoma Goals Human Immunosuppression Immunotherapy Incidence Individual Intracranial Neoplasms Investigation Kynurenine Malignant - descriptor Malignant Glioma Malignant Neoplasms Malignant neoplasm of brain Mediator of activation protein Modeling Multicenter Studies Nanoconjugate Nature Neoplasms Newly Diagnosed Operative Surgical Procedures Organ Patient-Focused Outcomes Patients Persons Primary Brain Neoplasms Production Prognosis Public Health RNA Interference Radiation Radiation therapy Records Recurrence Research Research Personnel Research Project Grants Residual Tumors Rodent Science Small Interfering RNA Spherical Nucleic Acids Surgically-Created Resection Cavity TP53 gene Talents Therapeutic Time Tissues Treatment outcome Ursidae Family Viral Virus Work antitumor effect base experience humanized mouse immune checkpoint blockade improved improved outcome inhibitor interdisciplinary approach member multidisciplinary nanoparticle nanotherapeutic neoplastic cell nerve stem cell novel novel therapeutics oncolytic virotherapy particle pre-clinical research preclinical study preservation programmed cell death protein 1 programs standard care standard of care statistics success survivorship temozolomide translational approach tumor

项目摘要

OVERVIEW: SUMMARY The overall objective of the Northwestern Brain Tumor SPORE is to improve outcomes for brain tumor patients. Statistics on brain tumor incidence indicate that more than 23,000 people will be diagnosed with a brain tumor in the U.S. in 2017, and approximately 17,000 will succumb to their disease. Of the various primary intracerebral neoplasms, glioblastoma (GBM) is the most common. GBM patients that receive standard-of-care treatment have a median survival of 15 months, and 5-year survival is extremely rare. Progress in developing better treatments for this lethal tumor has been disappointing. A major contributor to this lack of therapeutic improvement is the delicate nature of the organ in which this cancer occurs. There are significant limitations to how aggressively GBM patients can be treated surgically, and the efficacy of systemically administered therapies are often compromised due to limited access to the brain. To address the public health problem that is associated with glioblastoma, we have assembled a talented team of investigators with extensive backgrounds in brain tumor research and therapy. All members of this team have professional records indicating success in directing their own programs of research. Some 3+ years ago, these faculty initiated group interactions in order to bring a team science approach to bear upon the study and treatment of GBM, and for which a multidisciplinary approach is needed for achieving meaningful progress.

概述：摘要西北脑瘤孢子的总体目标是改善脑瘤的治疗结果病人。关于脑瘤发病率的统计数据表明，超过2.3万人将被诊断为脑瘤 2017年，美国将有大约17,000人死于脑瘤。不同的初选脑内肿瘤中，以胶质母细胞瘤(GBM)最为常见。接受标准护理的GBM患者治疗的中位生存期为15个月，5年生存率极其罕见。发展中的进步对于这种致命的肿瘤，更好的治疗方法令人失望。造成这种缺乏治疗的一个主要因素改善是这种癌症发生的器官的微妙性质。有很大的局限性 GBM患者的外科治疗力度有多大，全身给药的疗效如何由于接触大脑的途径有限，治疗方法经常受到影响。为了解决公共卫生问题，与胶质母细胞瘤有关，我们组建了一支才华横溢的调查团队，拥有广泛的脑瘤研究和治疗的背景。这个团队的所有成员都有职业记录表明他们成功地指导了他们自己的研究计划。大约3年前，这些教职员工发起了小组互动为了将团队科学方法应用于GBM的研究和治疗，为此，需要采取多学科方法，以取得有意义的进展。